Exclusive Summary

• Lamivudine patents have expired globally, leading to a mature but stable generic market with high demand, especially in HIV/HBV prevalent regions.
• Listed in WHO EML and recommended by major guidelines as a first-line or key second-line agent, it holds an indispensable position in HIV and HBV treatment.
• The product boasts established clinical efficacy and safety profiles, with extensive long-term use experience and high market acceptance.
• Generic lamivudine offers significant cost advantages over originator drugs, meeting the needs of low- and middle-income countries and public procurement.
• Market growth opportunities still exist in specific regions (e.g., Africa, Southeast Asia), where Chinese manufacturers' GMP certifications and cost-effectiveness can offer a competitive edge.